These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33560503)

  • 1. A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors.
    Yamamoto N; Shimizu T; Yonemori K; Kitano S; Kondo S; Iwasa S; Koyama T; Sudo K; Sato J; Tamura K; Tomomatsu J; Ono M; Fukuda N; Takahashi S
    Invest New Drugs; 2021 Aug; 39(4):1036-1046. PubMed ID: 33560503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
    Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
    Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models.
    Yoshimura C; Muraoka H; Ochiiwa H; Tsuji S; Hashimoto A; Kazuno H; Nakagawa F; Komiya Y; Suzuki S; Takenaka T; Kumazaki M; Fujita N; Mizutani T; Ohkubo S
    Mol Cancer Ther; 2019 Jul; 18(7):1205-1216. PubMed ID: 31092565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
    Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
    Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
    Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
    Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
    Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
    Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
    Yamamoto N; Ryoo BY; Keam B; Kudo M; Lin CC; Kunieda F; Ball HA; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T
    Invest New Drugs; 2020 Apr; 38(2):445-456. PubMed ID: 31041575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
    Blagden S; Omlin A; Josephs D; Stavraka C; Zivi A; Pinato DJ; Anthoney A; Decordova S; Swales K; Riisnaes R; Pope L; Noguchi K; Shiokawa R; Inatani M; Prince J; Jones K; Twelves C; Spicer J; Banerji U
    Clin Cancer Res; 2014 Dec; 20(23):5908-17. PubMed ID: 25231405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
    Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
    Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
    Doi T; Takahashi S; Aoki D; Yonemori K; Hara H; Hasegawa K; Takehara K; Harano K; Yunokawa M; Nomura H; Shimoi T; Horie K; Ogasawara A; Okame S
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):605-616. PubMed ID: 38411735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
    Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
    Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
    Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
    Mita M; Gordon M; Rejeb N; Gianella-Borradori A; Jego V; Mita A; Sarantopoulos J; Sankhala K; Mendelson D
    Target Oncol; 2014 Sep; 9(3):215-24. PubMed ID: 23832397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
    Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
    Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.